Stay Alert for Low-Dose Rivaroxaban for Coronary or Peripheral Artery Disease

You'll see a new rivaroxaban (Xarelto) 2.5 mg dose for patients with stable coronary artery disease (CAD) or peripheral artery disease (PAD).

Reps will call this a "vascular" dose. It's approved for BID use WITH aspirin 81 mg/day to reduce CV events in chronic CAD or PAD patients.

But don't expect it to be popular. Most patients will stick with aspirin alone...the margin of benefit of adding rivaroxaban is small.

Practical advice for a better career, with unlimited access to CE

Hospital Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote